Table 2.
Baseline characteristics of patients after matching.
| Variables | TACE | Control | p value | TACE + RFA | Control | p value |
|---|---|---|---|---|---|---|
| (n = 188) | (n = 188) | (n = 102) | (n = 102) | |||
| Median age (range) | 55 (25–78) | 54 (25–81) | 0.655a) | 57 (28–78) | 53 (25–80) | 0.068a) |
| Sex (M/F) | 164/24 | 160/28 | 0.500b) | 84/18 | 90/12 | 0.236b) |
| Family history of HCC (yes/no) | 24/164 | 25/163 | 0.878b) | 10/92 | 15/87 | 0.286b) |
| HBV related (yes/no) | 169/19 | 174/14 | 0.362b) | 93/9 | 94/8 | 0.800b) |
| GGT (IU/L) | 169.4 (86.8–190.4) | 197.9 (83.2–275.3) | 0.141c) | 101.5 (59.7–156.4) | 112.2 (60.4–185.3) | 0.711c) |
| WBC (×109/L) | 5.0 (3.4–5.8) | 5.1 (3.5–6.4) | 0.319c) | 4.5 (3.6–6.7) | 5.2 (3.8–6.3) | 0.955c) |
| PLT (×109/L) | 112.6 (61.7–143.8) | 126.9 (70.3–162.3) | 0.027c) | 111.8 (63.1–161.5) | 108.7 (69.9–164.4) | 0.898c) |
| AFP (ng/mL) (≥400/<400) | 90/98 | 88/100 | 0.836b) | 44/58 | 41/61 | 0.670b) |
| PVTT (%) | 154 (81.9) | 147 (78.2) | 0.480b) | 83 (81.4) | 85 (83.3) | 0.713b) |
| HVTT (%) | 11 (5.9) | 12 (6.4) | 1.000b) | 6 (5.9) | 6 (5.9) | 1.000b) |
| PVTT + HVTT (%) | 23 (12.2) | 29 (15.4) | 0.535b) | 13 (12.7) | 11 (10.8) | 0.663b) |
| Tumor number (≥3/<3) | 92/96 | 103/85 | 0.256b) | 41/61 | 38/64 | 0.666b) |
| Tumor diameter (cm) (≥5/<5) | 109/79 | 122/66 | 0.167b) | 56/46 | 67/35 | 0.115b) |
| Child-Pugh class (A/B or C) | 79/109 | 66/122 | 0.168b) | 53/49 | 50/52 | 0.674b) |
| MELD score | 6.8 (4.4–8.8) | 7.7 (4.8–9.6) | 0.672c) | 6.4 (3.4–8.8) | 7.4 (4.6–9.3) | 0.079c) |
| TNM (III/IV) | 153/35 | 155/33 | 0.789b) | 88/14 | 88/14 | 1.000b) |
| BCLC (C/D) | 160/28 | 162/26 | 0.769b) | 92/10 | 87/15 | 0.286b) |
Age is presented as median (range), categorical variables as number (%), continuous variable as mean (interquartile range). a), t-test; b), chi-square test or Fisher's exact test; c), Mann–Whitney U test. HBV, hepatitis B virus; GGT, gamma-glutamyl transferase; WBC, white blood cell count; PLT, platelet count; AFP, α-fetoprotein; PVTT, portal vein tumor thrombosis; HVTT, hepatic vein tumor thrombosis; MELD, model for end-stage liver disease; TNM, tumor, node, and metastasis staging; BCLC, Barcelona Clinic for Liver Cancer.